Latest Regulatory Approval News

Cuscal has secured the final regulatory approval from the French Works Council, paving the way to complete its $27 million acquisition of New Zealand payments provider Paymark by late May.

Ainsworth Game Technology’s FY25 results reveal a mixed bag: a 9% dip in underlying profit to $21.1 million, a hefty $43.1 million goodwill impairment tied to North America, and a strategic pivot with a new acting CEO. Strong Asia Pacific growth and new product launches contrast with margin pressures and a shrinking cash position.

Vulcan Energy has officially started full-scale construction of its Lionheart lithium chemicals facility in Frankfurt, targeting a 2028 commercial production start with a capacity to supply 500,000 EV batteries annually.

Qube Holdings Limited is set for a $9.3 billion cash takeover by a Macquarie-led consortium, with court approval granted to convene shareholder meetings in June. The scheme offers shareholders a 28% premium and is backed by an independent expert's fair and reasonable opinion.

Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.

Wide Open Agriculture appoints Craig Swan as CEO and pivots to a contract manufacturing model to improve economics and scale lupin protein production, while receiving a A$1.69 million R&D tax rebate.

Dreadnought Resources has obtained regulatory approval for open pit mining at its Star of Mangaroon gold project in Western Australia, advancing its strategy to become a self-funded explorer by outsourcing development and processing.

Little Green Pharma has pushed back the Federal Court hearing for its Cannatrek acquisition to late May, setting a new timetable that includes a shareholder vote on May 22 and implementation targeted for June 1.

Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.

Barton Gold has launched a ~3,000m diamond drilling campaign at its Tunkillia project, aiming to upgrade resources and support a Mining Lease application by the end of 2026. The project builds on a strong May 2025 study projecting robust returns amid rising gold and silver prices.

Macro Mining Services has partnered with Austral Pacific to tap into gold tailings and stockpiles at the Paris Gold Mine, aiming to turn historical waste into revenue through a 50:50 profit share after expense recovery.

Prospect Resources has significantly boosted its Mumbezhi Copper Project resource base by 63%, lifted contained copper by 50%, and secured A$45 million in fresh capital to fund an aggressive drilling campaign starting May 2026.